Establishment and biological characteristics of oxaliplatin-resistant human colon cancer cell lines

Chinese Journal of Cancer

Volumn 29, Issue 7, 2010, Pages 661-667

  Liu, Zhen ^a   Qiu, Meng ^a   Tang, Qiu Lin ^a   Liu, Ming ^a   Lang, Nan ^a   Bi, Feng ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

CD133; Colon neoplasm; Drug resistance; MRP2; Oxaliplatin; P gp, MRP1

Indexed keywords

CD133 ANTIGEN; CISPLATIN; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; GLYCOPROTEIN P; HERMES ANTIGEN; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 2; OXALIPLATIN; PACLITAXEL; VINCRISTINE;

ANTIGEN EXPRESSION; ARTICLE; CANCER CELL CULTURE; CELL CYCLE; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; COLON CANCER; CONTROLLED STUDY; CROSS RESISTANCE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; PHENOTYPE; PROTEIN ANALYSIS; PROTEIN EXPRESSION; TUMOR GROWTH; UPREGULATION; WESTERN BLOTTING;

EID: 79955847439     PISSN: 1000467X     EISSN: 1944446X     Source Type: Journal    
DOI: 10.5732/cjc.009.10666     Document Type: Article

References (26)

1. Segal NH, Saltz LB. Evolving treatment of advanced colon cancer [J]. Annu Rev Med, 2009, 60: 207-219.
2. Tourniqand C, Andre T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study [J]. J Clin Oncol, 2004, 22(2): 229-237.
3. Wu DL, Huang F, Lu HZ. Drug-resistant proteins in breast cancer: recent progress in multidrug resistance [J]. Chin J Cancer, 2003, 22(4): 441-4. [in Chinese]
4. Hong SP, Wen J, Park S, et al. CD44-positive cells are responsible for gemcitabine resistance in pancreatic cancer cells [J]. Int J Cancer, 2009, 125(10): 2323-2331.
5. Rabik CA, Dolan ME. Molecular mechanisms of resistance and toxicity associated with platinating agents [J]. Cancer Treat Rev, 2007, 33(1): 9-23.
6. Gossage L, Madhusudan S. Current status of excision repair cross complementing-group 1 (ERCC1) in cancer [J]. Cancer Treat Rev, 2007, 33(6): 565-577.
7. Liedert B, Materna V, Schadendorf D, et al. Overexpression of cMOAT (MRP2/ABCC2) is associated with decreased formation of platinum-DNA adducts and decreased G2-arrest in melanoma cells resistant to cisplatin [J]. J Invest Dermatol, 2003, 121(1): 172-176
8. Voland C, Bord A, Péleraux A, et al. Repression of cell cycle-related proteins by oxaliplatin but not cisplatin in human colon cancer cells [J]. Mol Cancer Ther, 2006, 5(9): 2149-2157.
9. Snow K, Judd WL. Characterisation of adriamycin and amsacrine-resistant human leukaemic T cell lines [J]. Br J Cancer, 1991, 63 (1): 17-28.
10. Rabik CA, Dolan ME. Molecular mechanisms of resistance and toxicity associated with platinating agents [J]. Cancer Treat Rev, 2007, 33(1): 9-23.
11. Yu ZC, Ding J, Bi F, et al. Reversal effects of mrp antisense RNA on the resistance of gastric cancer cell line SGC7901 to VCR [J]. Chin J Cancer Biother, 2000, 7(3): 174-176. [in Chinese]
12. Chen LM, Liang YJ, Zhang X, et al. Reversal of P-gp-mediated multidrug resistance by bromotetrandrine in vivo is associated with enhanced accumulation of chemotherapeutical drug in tumor tissue [J]. Anticancer Res. 2009, 29(11): 4597-4604.
13. Woodahl EL, Crouthamel MH, Bui T, et al. MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents [J]. Cancer Chemother Pharmacol. 2009, 64(1): 183-188.
14. Koehn J, Fountoulakis M, Krapfenbauer K. Multiple drug resistance associated with function of ABC-transporters in diabetes mellitus: molecular mechanism and clinical relevance [J]. Infect Disord Drug Targets. 2008, 8(2): 109-118.
15. Yuan SQ, Zhou ZW, Liang YJ, et al. Correlation of chemosensitivity measured by histoculture drug response assay to expression of multidrug resistance genes and proteins in gastric cancer [J]. Chin J Cancer, 2009, 28(4): 337-43. [in Chinese]
16. Zhai BJ, Wu F, Shao ZY, et al. Establishment of in vivo adriamycin-induced multidrug resistance models of subcutaneous and hepatic transplanted human liver cancer in nude mice [J]. Chin J Cancer, 2004, 23(8): 905-9. [in Chinese]
17. Bohácová V, Sulová Z, Dovinová I, et al. L1210 cells cultivated under the selection pressure of doxorubicin or vincristine express common mechanisms of multidrug resistance based on the overexpression of P-glycoprotein [J]. Toxicol In Vitro. 2006, 20(8): 1560-1568.
18. Cui Y, König J, Buchholz JK, et al. drug resistance and ATP-Dependent conjugate transport mediated by the apical multidrug resistance protein, MRP2, permanently expressed in human and canine cells[J]. Mol Pharmacol. 1999, 55(5): 929-937.
19. Yamada T, Tanaka N, Yokoi K, et al. Prediction of sensitivity to 5-fluorouracil (5-fu) by metabolic and target enzyme activities in colon cancer[J]. Gan To Kagaku Ryoho. 2006, 33(11): 1603-1609.
20. Oda S, Kuraoka I, Maehara Y. DNA repair as a determinant of tumour chemosensitivity [J]. Gan To Kagaku Ryoho. 2007, 34(3): 347-357.
21. Takano M, Otani Y, Tanda M, et al. Paclitaxel-resistance conferred by altered expression of efflux and influx transporters for paclitaxel in the human hepatoma cell line, HepG2 [J]. Drug Metab Pharmacokinet. 2009, 24(5): 418-427.
22. Zhou J, Cheng SC, Luo D, et al. Study of multi-drug resistant mechanisms in a taxol-resistant hepatocellular carcinoma QGY-TR 50 cell line [J]. Biochem Biophys Res Commun. 2001, 280(5): 1237-1242.
23. Mittal S, Mifflin R, Powell DW. Cancer stem cells: the other face of Janus[J]. Am J Med Sci. 2009, 338(2): 107-112.
24. Dean M. ABC transporters, drug resistance, and cancer stem cells [J]. Mammary Gland Biol Neoplasia. 2009, 14(1): 3-9.
25. Gangemi R, Paleari L, Orengo AM. Cancer stem cells: a new paradigm for understanding tumor growth and progression and drug resistance[J]. Curr Med Chem. 2009, 16(14): 1688-1703.
26. Nakai E, Park K, Yawata T, et al. Enhanced MDR1 Expression and Chemoresistance of Cancer Stem Cells Derived from Glioblastoma [J]. Cancer Invest,. 2009, 27(9): 901-908.